IDH2 and astrocytoma (excluding glioblastoma): Combined WHO classification and proteomic subtyping, we clearly demonstrated that WHO_Grade4_IDH-mutant_astrocytomas featured with CDKN2A/B homozygous deletion could be grouped into S-Pf proteomic subtype, supported by their enhanced cell proliferation ability at protein level.